Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with saquinavir

S Vella1

  • 1Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.

AIDS (London, England)
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Saquinavir, an HIV protease inhibitor, effectively increases CD4 counts and reduces HIV RNA levels when used in combination therapy. Clinical trials show saquinavir is well-tolerated in patients with HIV, including those with advanced disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging of primary malignant tumors in non-cirrhotic liver.

Diagnostic and interventional imaging·2020
Same author

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons.

The Journal of frailty & aging·2019
Same author

Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

A cross-sectional analysis of daytime versus nocturnal polysomnographic respiratory parameters in cystic fibrosis during early adolescence.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2016
Same author

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment.

Journal of immigrant and minority health·2016
Same author

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

The West Indian medical journal·2015
Same journal

Clinical implications of the new definition of obesity among persons with HIV.

AIDS (London, England)·2026
Same journal

Cabotegravir and rilpivirine resistance-associated mutations among people with newly diagnosed HIV-1 in the Netherlands.

AIDS (London, England)·2026
Same journal

Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.

AIDS (London, England)·2026
Same journal

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
Same journal

Genome-wide association study of cardiovascular disease in people with HIV from the Million Veteran Program (MVP).

AIDS (London, England)·2026
Same journal

The US President's Emergency Plan for AIDS Relief-funded service integration protected children from tuberculosis.

AIDS (London, England)·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Immunology

Background:

  • Saquinavir is a potent and specific inhibitor of HIV-1 and HIV-2 proteases.
  • It acts as a peptide-based, transition-state analogue of the HIV proteinase cleavage site.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of saquinavir in combination therapy for HIV infection.
  • To assess the impact of saquinavir on CD4 cell counts and HIV-1 RNA levels.

Main Methods:

  • Combination therapy trials involving saquinavir with zidovudine and/or zalcitabine.
  • Evaluation of immunological and virological responses in antiretroviral-naive and previously treated patients.

Main Results:

  • Combination therapy with saquinavir and zidovudine demonstrated greater and more sustained increases in CD4 counts and decreases in HIV-1 RNA than monotherapy.

Related Experiment Videos

  • Triple combination therapy including saquinavir showed superior immunological and virological responses compared to dual therapy in previously treated patients.
  • Saquinavir was well-tolerated in clinical experience, even in patients with advanced HIV disease.

    • Conclusions:

    • Saquinavir is an effective component of combination antiretroviral therapy for HIV infection.
    • Combination regimens including saquinavir offer significant immunological and virological benefits.
    • Saquinavir demonstrates a favorable tolerability profile in diverse HIV patient populations.